TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02941367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT00235157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Palmaz Genesis peripheral stent
Description: treatment of renal artery stenosis with a renal stent
Study: NCT02896842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Study: NCT03175939

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiotherapy with curative intent, at least 66 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin IV injection over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU IV 24 hours continuous infusion
Study: NCT00168298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 µg Dexamethasone
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection on Day 0.
Study: NCT02338830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
Study: NCT04253730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stress
Description: 60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
Study: NCT04831112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Dressing of necrotizing fascitis wounds with honey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: Dressing of necrotizing fascitis wounds with honey.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EUSOL
Description: Dressing of necrotizing fascitis wounds with EUSOL.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EUSOL
Description: Dressing of necrotizing fascitis wounds with EUSOL.
Study: NCT00927043

Intervention type: OTHER
Intervention: Epidemiological study according to clinical practice
Description: Epidemiological study according to clinical practice.
Study: NCT02397252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eve Medical self-collection system©
Description: The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cobas® PCR Female swab self-sampling
Description: Regular polyester swab for collection of vaginal cells.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physician-collected sampling
Description: Routine colposcopy sample collected by a physician.
Study: NCT02966314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
Study: NCT03784378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-105
Description: RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
Study: NCT01474577

Intervention type: OTHER
Intervention: questionnaire
Description: Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
Study: NCT00391976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 300 mg
Description: Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 300 mg
Description: Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
Study: NCT03849729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
Study: NCT02582515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00573599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prochlorperazine and benadryl IV
Description: prochlorperazine and benadryl IV, saline subQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex SubQ, saline IV
Description: Imitrex SubQ, saline IV
Study: NCT01196000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic surgery
Description: operation using conventional laparoscopic techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic surgery
Description: operation that involves use of laparoscopic assistance with robotic assistance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01274039

Intervention type: DRUG
Intervention: Acetazolamide for glaucoma patients to lower eye pressure
Description: Acetazolamide tablets 3 times daily for 3 to 4 weeks
Study: NCT04052503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Broker
Description: Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge Broker
Description: Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
Study: NCT02527109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Study: NCT02821728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal diet
Description: Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
Study: NCT01379222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft System
Description: The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
Study: NCT03183986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Phototherapy for 24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Phototherapy for 24 hours.
Study: NCT03429712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-source multi-detector computed tomography (DSSE)
Description: Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
Study: NCT03944330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard hospital diet
Description: patients were provided standard hospital diet that provided 25-30 kcal/kg/day
Study: NCT04086186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine Peri-articular Injection
Description: A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
Study: NCT03809130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use Untire application after baseline up to 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Use Untire application after 3 months up to 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01152840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn.
Study: NCT00739947

Intervention type: OTHER
Intervention: Observational study of the surgical outcome
Description: Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
Study: NCT02548234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral arm training
Description: Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
Study: NCT03133637

Intervention type: DRUG
Intervention: ceftriaxone
Description: Eligible infants will receive ceftriaxone as standard of care for sepsis
Study: NCT03036085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
Study: NCT04555889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung recruitment maneuver (LRM) with DrageerVN500
Description: interventions involving device that may help to gradually lung development
Study: NCT02957994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate
Description: Patients on TDF will be switched to TAF
Study: NCT03155425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized monoclonal immunoglobulin
Study: NCT02167386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP Adherence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard PrEP Adherence
Study: NCT04055584

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum
Description: DNA extraction and perform a diversity of molecular diagnostic tests
Study: NCT00446563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg film coated tablets taken orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg or 10 mg tablets taken orally once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 12.5 mg or 25 mg tablets taken orally once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg tablets taken orally once daily in the morning.
Study: NCT02213055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LICEMD
Description: Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Head lice product
Description: The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
Study: NCT02361593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assistance of a transparent cap
Description: Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
Study: NCT01223105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow freeze
Description: Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification
Description: Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
Study: NCT04229121

Intervention type: OTHER
Intervention: nonintervention
Description: nonintervention

Intervention type: OTHER
Intervention: nonintervention
Description: nonintervention
Study: NCT04535076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: Transcatheter Aortic Valve Implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement
Description: Surgical Aortic Valve Replacement
Study: NCT01330576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling blanket/mattress
Description: Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment of care at normothermia
Description: Standard treatment of care in 33.5C for 48 hours
Study: NCT04187352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001+ Fluorouracil+Cisplatin
Description: CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+ Fluorouracil+Cisplatin
Description: Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Study: NCT01488058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxIGen + iCBT
Description: OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Waitlist will receive iCBT at week 11
Study: NCT04306133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Infiltration
Description: At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
Study: NCT02494479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prurisol
Description: 50mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prurisol
Description: 50mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prurisol
Description: 50mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to match Purisol tablet
Study: NCT03531021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart healthy intervention
Description: Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
Study: NCT00667212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Twelve weekly therapy sessions, approximately one hour each in duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Twelve weekly therapy sessions, approximately one hour each in duration
Study: NCT02902211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control/standard of care
Description: Patients will carry out with typical activities suggested by their physician for three months.